Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Human Erythropoietin for Acute Renal Failure Prevention in ICU
NCT00676234Phase 2Completed
- Start
- May 2008
- Primary completion
- Jun 2009
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epoetin alfa in acute kidney injury (AKI) (3 arms). Primary endpoint: Urinary Neutrophil Gelatinase-Associated Lipocalin concentration at 96 hours. Started May 2008; status: completed.
02
Drugs
epoetin alfa
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT00676234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00676234.